JP7644002B2 - 多形化合物およびその使用 - Google Patents

多形化合物およびその使用 Download PDF

Info

Publication number
JP7644002B2
JP7644002B2 JP2021522528A JP2021522528A JP7644002B2 JP 7644002 B2 JP7644002 B2 JP 7644002B2 JP 2021522528 A JP2021522528 A JP 2021522528A JP 2021522528 A JP2021522528 A JP 2021522528A JP 7644002 B2 JP7644002 B2 JP 7644002B2
Authority
JP
Japan
Prior art keywords
compound
present
patient
pharma
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021522528A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505849A5 (cg-RX-API-DMAC7.html
JP2022505849A (ja
Inventor
シルヴィア レンツィーニ,
Original Assignee
ナビター ファーマシューティカルズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナビター ファーマシューティカルズ, インコーポレイテッド filed Critical ナビター ファーマシューティカルズ, インコーポレイテッド
Publication of JP2022505849A publication Critical patent/JP2022505849A/ja
Publication of JP2022505849A5 publication Critical patent/JP2022505849A5/ja
Priority to JP2024174435A priority Critical patent/JP2025000975A/ja
Application granted granted Critical
Publication of JP7644002B2 publication Critical patent/JP7644002B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/04—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
    • C07C225/06—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
JP2021522528A 2018-10-24 2019-10-24 多形化合物およびその使用 Active JP7644002B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024174435A JP2025000975A (ja) 2018-10-24 2024-10-03 多形化合物およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862749922P 2018-10-24 2018-10-24
US62/749,922 2018-10-24
PCT/US2019/057815 WO2020086816A1 (en) 2018-10-24 2019-10-24 Polymorphic compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024174435A Division JP2025000975A (ja) 2018-10-24 2024-10-03 多形化合物およびその使用

Publications (3)

Publication Number Publication Date
JP2022505849A JP2022505849A (ja) 2022-01-14
JP2022505849A5 JP2022505849A5 (cg-RX-API-DMAC7.html) 2022-10-31
JP7644002B2 true JP7644002B2 (ja) 2025-03-11

Family

ID=70328246

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021522528A Active JP7644002B2 (ja) 2018-10-24 2019-10-24 多形化合物およびその使用
JP2024174435A Pending JP2025000975A (ja) 2018-10-24 2024-10-03 多形化合物およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024174435A Pending JP2025000975A (ja) 2018-10-24 2024-10-03 多形化合物およびその使用

Country Status (8)

Country Link
US (4) US11345654B2 (cg-RX-API-DMAC7.html)
EP (1) EP3870158A4 (cg-RX-API-DMAC7.html)
JP (2) JP7644002B2 (cg-RX-API-DMAC7.html)
CN (1) CN113164414A (cg-RX-API-DMAC7.html)
AU (2) AU2019364542B2 (cg-RX-API-DMAC7.html)
CA (1) CA3117336A1 (cg-RX-API-DMAC7.html)
MX (2) MX2021004710A (cg-RX-API-DMAC7.html)
WO (1) WO2020086816A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX389001B (es) 2015-10-23 2025-03-20 Navitor Pharm Inc Moduladores de interacción de sestrina-gator2 y sus usos.
ES3040534T3 (en) 2017-04-26 2025-11-03 Navitor Pharm Inc Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression
WO2020086816A1 (en) 2018-10-24 2020-04-30 Navitor Pharmaceuticals, Inc. Polymorphic compounds and uses thereof
AU2020376950B2 (en) 2019-11-01 2026-06-11 Supernus Pharmaceuticals, Inc. Methods of treatment using an mTORC1 modulator
CN115927459A (zh) * 2022-07-19 2023-04-07 华南农业大学 猪ctns基因在促进动物骨骼肌生长中的应用
KR20250111125A (ko) * 2022-11-01 2025-07-22 나비토르 파마슈티칼스 인코포레이티드 mTORC1 활성의 조절제 및 이의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017501113A (ja) 2013-10-23 2017-01-12 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ アミノ酸によるmTORC1の調節およびその使用
WO2017070518A1 (en) 2015-10-23 2017-04-27 Navitor Pharmaceuticals, Inc. Modulators of sestrin-gator2 interaction and uses thereof
JP2018507910A (ja) 2015-02-12 2018-03-22 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ジ・ユニバーシティ・オブ・アリゾナ 神経芽細胞腫を治療する方法
JP2018065772A (ja) 2016-10-21 2018-04-26 国立大学法人山口大学 mTORC1活性化抑制剤

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110368A (en) 1972-07-24 1978-08-29 American Cyanamid Company Hydro substituted prostanoic acids and esters
US4346110A (en) 1981-06-01 1982-08-24 Merrell Toraude Et Compagnie Method for treating depression
JPS61149964A (ja) 1984-12-25 1986-07-08 Canon Inc 電子写真感光体
US4670196A (en) 1985-09-05 1987-06-02 Norton Company Tower packing element
ES2029799T3 (es) 1986-01-24 1992-10-01 Toray Industries, Inc. Derivados de 2,5,6,7 tetranor-4,8-inter-m-fenilen pg12.
GB8827885D0 (en) 1988-11-30 1989-01-05 Wellcome Found Novel heterocyclic pesticidal compounds
US5639600A (en) 1994-08-05 1997-06-17 The Regents Of The University Of California Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement
DE19623142A1 (de) 1996-06-10 1997-12-11 Huels Chemische Werke Ag Enantiomerenangereicherte, durch einen tertiären Kohlenwasserstoffrest substituierte Malonsäuremonoester sowie deren Herstellung
HUP9903916A3 (en) 1996-08-28 2001-06-28 Procter And Gamble Co Cincinna Phosphinic acid amides and pharmaceutical compositions containing the same
US7087648B1 (en) 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
WO1999055688A1 (en) 1998-04-27 1999-11-04 Warner-Lambert Company Substituted diarylalkyl amides as calcium channel antagonists
BR9907140A (pt) 1998-11-04 2000-10-17 Montell Technology Company Bv Componentes catalìticos sólidos, catalisadores e processo para a (co) polimerização de olefinas ch2=chr.
US6329546B1 (en) 1999-01-12 2001-12-11 Laboratory Of Molecular Biophotonics Caged amino acids
US20030203900A1 (en) 1999-05-18 2003-10-30 Martin Quibell Cysteine protease inhibitors
CZ300834B6 (cs) 1999-06-10 2009-08-19 Warner-Lambert Company Llc Mono- a disubstituované kyseliny 3-propyl-gamma-aminomáselné
KR100833371B1 (ko) 2001-04-27 2008-05-28 젠야쿠코교가부시키가이샤 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA05001766A (es) 2002-08-14 2005-08-19 Atugen Ag Uso de proteina quinasa n beta.
US6787664B2 (en) 2002-09-17 2004-09-07 Warner-Lambert Company Llc Process for preparing single enantiomers of 5,5,5,5′,5′,5′-hexafluoroleucine and protected analogs
AU2002953255A0 (en) 2002-12-11 2003-01-02 Cytopia Research Pty Ltd Protein kinase inhibitors
WO2004089925A1 (en) 2003-04-03 2004-10-21 Semafore Pharmaceuticals, Inc. Pi-3 kinase inhibitor prodrugs
ES2382377T3 (es) 2003-05-30 2012-06-07 Gemin X Pharmaceuticals Canada Inc. Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
WO2005007623A2 (en) 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
US20070212428A1 (en) 2004-06-04 2007-09-13 Mood Management Sciences, Inc. Methods and compositions for treating mood disorder
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
MX2007009985A (es) 2005-02-18 2008-03-11 Innodia Inc Diastereoisomeros de 4-hidroxiisoleucina y usos de los mismos.
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
HRP20140975T1 (hr) 2005-10-07 2014-11-21 Exelixis, Inc. Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
KR101533461B1 (ko) 2006-04-26 2015-07-02 에프. 호프만-라 로슈 아게 Pi3k저해제로 유용한 티에노[3,2-d]피리미딘 유도체
CN101573334A (zh) 2006-08-21 2009-11-04 普雷萨药品公司 用于治疗中枢神经系统障碍的多介质转运体抑制剂
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
EP2069339B1 (en) 2006-09-25 2011-05-18 Wockhardt Research Centre Substituted piperidinophenyl oxazolidinones
TWI397418B (zh) 2006-10-10 2013-06-01 Otsuka Pharma Co Ltd 抗憂鬱劑
RU2009118935A (ru) 2006-10-20 2010-11-27 Мерк энд Ко., Инк. (US) Земещенные имидазолы в качестве модуляторов подтипа 3 бомбезиновых рецепторов
HUE029188T2 (en) 2007-03-12 2017-03-28 Ym Biosciences Australia Pty Phenylamino-pyrimidine compounds and their use
US8394794B2 (en) 2007-03-23 2013-03-12 Regents Of The University Of Minnesota Therapeutic compounds
TW200902019A (en) 2007-04-26 2009-01-16 Ono Pharmaceutical Co Dicyclic heterocyclic compound
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
US8431608B2 (en) 2007-08-17 2013-04-30 Icagen Inc. Heterocycles as potassium channel modulators
US8445686B2 (en) 2007-08-27 2013-05-21 Abbvie Inc. 4-(4-pyridinyl)-benzamides and their use as rock activity modulators
MY165582A (en) 2008-03-11 2018-04-05 Incyte Holdings Corp Azetidine and cyclobutane derivatives as jak inhibitors
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
JP2012530116A (ja) 2009-06-19 2012-11-29 レツク・フアーマシユーテイカルズ・デー・デー 脱ハロゲン化なしにハロゲノアルケンを水素化する方法
US20120219596A1 (en) 2009-07-30 2012-08-30 Wendelin Stark Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event
CA2786245A1 (en) 2010-01-29 2011-08-04 Boehringer Ingelheim International Gmbh Substituted naphthyridines and their use as syk kinase inhibitors
JP5744021B2 (ja) 2010-06-30 2015-07-01 富士フイルム株式会社 新規なニコチンアミド誘導体またはその塩
CN102464701B (zh) 2010-11-08 2015-10-21 上海医药工业研究院 一类新型化合物、其制备方法及用途
WO2012076063A1 (en) 2010-12-10 2012-06-14 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
EP2678037B1 (en) 2011-02-25 2014-12-03 Lonza Ltd Branched linker for protein drug conjugates
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
US8987456B2 (en) 2011-10-05 2015-03-24 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
WO2013142229A1 (en) 2012-03-19 2013-09-26 President And Fellows Of Harvard College Designing novel peptides for inducing fibronectin matrix assembly
EP3202397B1 (en) 2012-08-06 2019-09-25 Pitney Pharmaceuticals Pty Limited Compounds for the treatment of mtor pathway related diseases
US20160002159A1 (en) 2013-02-13 2016-01-07 Neal ZONDLO Perfluoro-tert-butyl hydroxyproline
WO2014145852A2 (en) 2013-03-15 2014-09-18 Knopp Biosciences Llc Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
WO2014201111A1 (en) * 2013-06-14 2014-12-18 The Brigham And Women's Hospital, Inc. Treatment of mtor hyperactive related diseases and disorders
WO2017083823A1 (en) 2015-11-13 2017-05-18 Brandeis University Mtor inhibitors and methods of use thereof
US10512656B2 (en) * 2016-04-21 2019-12-24 Baylor College Of Medicine Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction
ES3040534T3 (en) 2017-04-26 2025-11-03 Navitor Pharm Inc Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression
US10653652B2 (en) 2018-02-08 2020-05-19 Ovid Therapeutics Inc. Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere'S disease, tourette'S syndrome, attention deficit hyperactivity disorder and addiction
WO2020086816A1 (en) 2018-10-24 2020-04-30 Navitor Pharmaceuticals, Inc. Polymorphic compounds and uses thereof
US10926803B2 (en) 2019-07-17 2021-02-23 GM Global Technology Operations LLC Four rail front crush structure with load dissemination into eight element support structure
AU2020376950B2 (en) 2019-11-01 2026-06-11 Supernus Pharmaceuticals, Inc. Methods of treatment using an mTORC1 modulator

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017501113A (ja) 2013-10-23 2017-01-12 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ アミノ酸によるmTORC1の調節およびその使用
JP2018507910A (ja) 2015-02-12 2018-03-22 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ジ・ユニバーシティ・オブ・アリゾナ 神経芽細胞腫を治療する方法
WO2017070518A1 (en) 2015-10-23 2017-04-27 Navitor Pharmaceuticals, Inc. Modulators of sestrin-gator2 interaction and uses thereof
JP2018065772A (ja) 2016-10-21 2018-04-26 国立大学法人山口大学 mTORC1活性化抑制剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BYRN S,PHARMACEUTICAL SOLIDS: A STRATEGIC APPROACH TO REGULATORY CONSIDERATIONS,PHARMACEUTICAL RESEARCH,米国,KLUWER ACADEMIC PUBLISHERS,1995年07月01日,V12 N7,pp.945-954
TERENCE L THRELFALL,ANALYSIS OF ORGANIC POLYMORPHS A REVIEW,ANALYST,1995年10月,VOL.120,pp.2435-2460,http://pubs.rsc.org/en/content/articlepdf/1995/AN/AN9952002435
大嶋寛,結晶多形・擬多形の析出挙動と制御,PHARM STAGE,2007年,Vol.6, No.10,pp.48-53,http://pubs.rsc.org/en/content/articlepdf/1995/AN/AN9952002435

Also Published As

Publication number Publication date
US20200131114A1 (en) 2020-04-30
EP3870158A4 (en) 2022-08-10
JP2025000975A (ja) 2025-01-07
US11345654B2 (en) 2022-05-31
US12252456B2 (en) 2025-03-18
US11697633B2 (en) 2023-07-11
EP3870158A1 (en) 2021-09-01
US20240018091A1 (en) 2024-01-18
CN113164414A (zh) 2021-07-23
US20220371985A1 (en) 2022-11-24
AU2019364542B2 (en) 2025-08-28
CA3117336A1 (en) 2020-04-30
MX2021004710A (es) 2021-06-04
WO2020086816A1 (en) 2020-04-30
US20250188017A1 (en) 2025-06-12
MX2025010903A (es) 2025-10-01
AU2019364542A1 (en) 2021-06-10
AU2025271494A1 (en) 2026-01-08
JP2022505849A (ja) 2022-01-14

Similar Documents

Publication Publication Date Title
JP2025000975A (ja) 多形化合物およびその使用
EP3596040B1 (en) Polymorphic salt of 6-chloro-3-amino-2(2-hydroxypropyl)quinoline and uses thereof
EP3920912B1 (en) Treatment of ciliopathies using inhibitors of glucosylceramide synthase (gcs)
BR112016009488B1 (pt) piperidil-etil-pirimidina substituída, seus usos, e composição farmacêutica
EP3685838A1 (en) Compound for treatment or prevention of obesity or diseases related to obesity, and application thereof
JP2016535101A (ja) 心臓リモデリング及び他の心疾患の治療
EP4316487A1 (en) Composition for preventing or treating neurodegenerative disease comprising compound inducing expression of anti-aging gene klotho
US20230137092A1 (en) Composition and Method for the Treatment and Prevention of Cardiac, Pulmonary, Dermal, and Renal Fibrosis
JP2012533537A (ja) コルホルシンダロパートを含む骨疾患の予防または治療用組成物
CA3176384A1 (en) Method of treating ship1-mediated diseases using pelorol derivatives
JP5849336B2 (ja) アデニル酸シクラーゼの活性調節剤
CN117466866B (zh) Hedgehog信号通路抑制剂
WO2020249120A9 (zh) 氨基硫醇类化合物作为脑神经或心脏保护剂的用途
JP6185650B2 (ja) 5−ht4受容体アゴニストとしての5−アミノ−キノリン−8−カルボキサミド誘導体
EP2473038A1 (en) Compounds for treating disorders or diseases associated with neurokinin 2 receptor activity
WO2024097285A1 (en) MODULATORS OF mTORC1 ACTIVITY AND USES THEREOF
CN112843041A (zh) 迷迭香酸或其衍生物作为新型trpc1拮抗剂的药用制备及其应用
EP4624482A1 (en) Pyrimidopyrimidinone compound and pharmaceutical composition comprising same
CN116120335A (zh) 作为Wnt信号通路激动剂的莪术醇衍生物及其制法和应用
WO2019114501A1 (zh) α-楝子素衍生物及其制备方法与应用
US20190040014A1 (en) Solid Forms of an S-Nitrosoglutathione Reductase Inhibitor
CN108586484A (zh) 噻吩并噻喃甲酰胺类化合物及其应用
HK1247126A1 (zh) 二羧酸的双酰胺衍生物作爲用於刺激组织再生和恢复减退的组织功能的药剂
HK1177391A (en) Compounds for treating disorders or diseases associated with neurokinin 2 receptor activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221021

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240325

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241125

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250214

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250227

R150 Certificate of patent or registration of utility model

Ref document number: 7644002

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113